Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL) regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv region so that the binding molecule binds to two different antigens.

Abstract: Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.

Abstract: The present invention relates to a TNF-? (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-? specific antibody, is a bispecific antibody that effectively binds to both TNF-? and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-?/CXCL10. A composition of the present invention comprises a TNF-?/CXCL-10 double targeting antibody which effectively binds to both TNF-? and CXCL10. The double targeting antibody of the present invention has excellent TNF-? inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-? or CXCL10 single targeting antibody.

Abstract: The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 or a fragment thereof with a human antibody Fc region. Also provided are health functional foods containing a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 (delta-like 1 homolog) or a fragment thereof with a human antibody Fc region as an active ingredient.

Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.

Abstract: The present invention relates to a TNF-? (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-? specific antibody, is a bispecific antibody that effectively binds to both TNF-? and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-?/CXCL10. A composition of the present invention comprises a TNF-?/CXCL-10 double targeting antibody which effectively binds to both TNF-? and CXCL10. The double targeting antibody of the present invention has excellent TNF-? inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-? or CXCL10 single targeting antibody.

Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.